Innovent recruits Sanofi’s global head of research as group president



Suzhou-based Innovent Biologics Inc., (HKEX.01801) announced the appointment of a group president to head global R&D, portfolio strategy, business development, and international operations. Dr. Liu Yong Jun is the appointee, and will report to Innovent’s founder and CEO Dr. Michael Yu.

Dr. Yong has a prestigious research background in immunology, oncology, and translational medicine. Early industry roles included senior scientist positions at Schering-Plough from 1991, while he began an academic career in 2002, serving as chairman of the immunology department and founder of the Center for Cancer Immunology Research at the University of Texas, MD Anderson Cancer Center. In 2011 Dr. Liu joined the Baylor Immunology Research Institute, and finally rejoined industry with AstraZeneca subsidiary Medimmune as Chief Scientific Officer (CSO) from 2014. Prior to joining Innovent, Dr. Liu served as global head of research at Sanofi from 2016 to 2020.

Reference:

Related news
Mexican authorities last week revealed that the SARS-CoV-2 vaccine advanced purchases that were announced recently will include 51 million doses from the World Health Organization (WHO)’s COVAX initiative, up to 34 million of Pfizer’s double-dose immunization, 77 million of AstraZeneca (AZ)’s double-dose vaccine, and 35 million of CanSino’s single-dose treatment, totalling 197 million doses for 116.7 million people.
China-based Realcan Pharmaceutical Group Co., Ltd (002589.SZ) announced the signing of a memorandum of understanding (MOF) to establish a strategic collaboration with the UK major AstraZeneca (AZ; NYSE.AZN).
China-based Akeso Biopharma (9926.HK) announced first patient enrollment in a Phase Ib multi-dose escalation clinical study for AK120 in moderate to severe atopic dermatitis (AD).
China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA:600196; HKG:02196) announced a licensing agreement between its subsidiary Shanghai Henlius Pharmaceutical Co., Ltd (HKEX.02696) and compatriot firm Essex Bio-Technology Co., Ltd, in relation to HLX04, Henlius's biosimilar version of the Roche-originated Avastin (bevacizumab).
Peru’s Ministry of Health (MINSA) this week revealed the state of negotiations to procure SARS-CoV-2 vaccines.
Recent news
Mexican authorities last week revealed that the SARS-CoV-2 vaccine advanced purchases that were announced recently will include 51 million doses from the World Health Organization (WHO)’s COVAX initiative, up to 34 million of Pfizer’s double-dose immunization, 77 million of AstraZeneca (AZ)’s double-dose vaccine, and 35 million of CanSino’s single-dose treatment, totalling 197 million doses for 116.7 million people.
According to GBI analysis, Chile's Institute of Public Health (ISP) this week published the approvals of US firm Pfizer’s biosimilar Ruxience (rituximab), Netherlands-based Synthon’s Gatrel (sunitinib), a first-in-market generic version of Pfizer’s Sutent, as well as Argentina-based Varifarma’s Nibclus (ponatinib), a first-mover generic of Pint Pharma’s Iclusig.
Brazil’s Ministry of Science, Technology, Innovation and Communication (MCTIC) this week announced results of a clinical trial (CT) evaluating the efficacy of broad-range antiviral nitazoxanide against early-stage COVID-19.
Óscar Vicente Scavone, president of Paraguay-based Laboratorios Éticos, last week commented on the local pharmaceutical industry’s situation and prospects amid the COVID-19 pandemic.
Russian bank and financial services giant Sberbank and compatriot pharma firm JSC Pharmasyntez signed a cooperation agreement on October 14, 2020.
The National Healthcare Security Administration (NHSA) released a notification in relation to the diagnosis-related group (DRG)-style payment pilot work plan, including plans to roll out an “index/points” system that will enable DRG.
China food delivery giant Meituan struck up a strategic partnership with Germany-based giant Bayer’s Consumer Health Division in China.
Analytics Snapshot


Analytics Snapshot